Assessing the influence of the COVID-19 pandemic on the incidence, clinical presentation, and clindamycin resistance rates of Streptococcus pyogenes infections.

Publication date: Jun 01, 2024

Streptococcus pyogenes (group A Streptococcus [GAS]) is a prevalent cause of community-acquired bacterial infections, with invasive GAS (iGAS) infections presenting severe morbimortality. Clindamycin is generally used based on its antitoxin effect. This study investigates changes in iGAS incidence, clinical presentation, outcomes, and clindamycin resistance in an adult cohort. This is a retrospective analysis of S. pyogenes episodes from a tertiary adult hospital in Barcelona (Spain) between 2015 and 2023. The pre-pandemic period includes data from 2015-2019. The pandemic period, from 2020-2021, and post-pandemic period comprised 2022 to the first semester of 2023. The global incidence of GAS infections in the pre-pandemic and post-pandemic periods were 2. 62 and 2. 92 cases per 10. 000 hospital admissions, whereas for iGAS cases, they were 1. 85 and 2. 34. However, a transient decrease was observed during the pandemic period: 1. 07 and 0. 78 per 10. 000 hospital admissions. There was a significant decrease in GAS and iGAS infections during the pandemic period compared with the pre-pandemic incidence (P

Concepts Keywords
Pandemic Clindamycin resistance
Semester COVID-19 pandemic
Spain S. pyogenes
Streptococcus

Semantics

Type Source Name
disease MESH COVID-19 pandemic
drug DRUGBANK Clindamycin
disease MESH infections
disease MESH bacterial infections
disease MESH group A streptococcal infections

Original Article

(Visited 1 times, 1 visits today)